肾细胞癌辅助免疫治疗现状及复发管理:一项欧洲德尔菲研究见解
该德尔菲研究邀请15名肾细胞癌专家于2024年7月至11月进行两轮调查,评估67个条目中39个(58.2%)达成共识(≥75%一致)。专家就辅助帕博利珠单抗的患者选择、启动时机、PD-L1不限、KIM-1作为复发风险生物标志物、ICI难治定义及寡转移局部治疗等达成共识,但特定亚组ICI挽救治疗未达共识。
要点
- 专家共识:使用Leibovich评分选择辅助帕博利珠单抗患者(79%),术后90天内启动治疗(86%),不限制PD-L1阳性(100%)。
- 血浆KIM-1被认为是潜在有用的复发风险生物标志物(93%),ICI难治定义为辅助治疗后6个月内复发(80%)。
- 寡转移复发支持局部治疗(80%),ICI难治患者支持靶向治疗或临床试验入组(87%),贝组替凡推荐用于ICI及多靶点TKI后的四线或更后线(93%)。
核心结论
- 该德尔菲研究提供了关于辅助免疫治疗在局限性肾细胞癌中不断演变的作用及复发管理的见解,多学科方法和定期评估对优化治疗策略至关重要。
研究设计与样本
- 两轮德尔菲研究,于2024年7月至11月进行,15名肾细胞癌专家参与,包含43个核心调查条目,分为67个组成部分进行综合评估。
主要发现
- 67个条目中39个(58.2%)达成共识(定义为≥75%一致)。
- 专家共识:使用Leibovich评分选择辅助帕博利珠单抗患者(79%),术后90天内启动治疗(86%),不限制治疗于PD-L1阳性肿瘤(100%)。
- 血浆KIM-1被专家认为是潜在有用的复发风险生物标志物(93%)。
- ICI难治性疾病定义为辅助治疗后6个月内复发(80%)。
- 支持寡转移复发的局部治疗(80%),以及ICI难治患者的靶向治疗或临床试验入组(87%)。
关键数值与推荐
- 共识阈值:≥75%一致。
- 辅助帕博利珠单抗患者选择:Leibovich评分(79%共识)。
- 辅助治疗启动时机:术后90天内(86%共识)。
- PD-L1状态:不限制治疗于PD-L1阳性肿瘤(100%共识)。
- 复发风险生物标志物:血浆KIM-1(93%共识)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Adjuvant immunotherapy has remarkably advanced the management of localized renal cell carcinoma (RCC) in patients at high risk of post-surgery recurrence. This Delphi study aimed to establish expert consensus on its use and subsequent management of relapse. METHODS: Fifteen RCC experts participated in a two-round Delphi process between July and November 2024. The study included 43 core survey items, divided into 67 components for comprehensive evaluation. RESULTS: Consensus, defined as ≥ 75 % agreement, was achieved for 39 of 67 items (58.2 %). Experts agreed on using the Leibovich score for selecting patients for adjuvant pembrolizumab (79 %), initiating therapy within 90 days post-surgery (86 %), and not restricting treatment to programmed death ligand-1 (PD-L1)-positive tumors (100 %). Plasma kidney injury molecule-1 (KIM-1) was considered by the experts as a potential useful recurrence risk biomarker (93 %). Immune checkpoint inhibitor (ICI)-refractory disease was defined as relapse within 6 months post-adjuvant therapy (80 %). Focal therapies for oligometastatic recurrence (80 %), and targeted therapies or clinical trial enrollment for ICI-refractory patients (87 %) were supported. Belzutifan was recommended for fourth-line or later use after ICI therapy and multiple tyrosine kinase inhibitors (93 %). By contrast, no consensus was reached on ICI salvage therapy in specific subgroups, including patients with clear-cell RCC (60 %), without bone/brain metastases (60 %), good performance status (60 %), low tumor burden (47 %), or papillary RCC (36 %). CONCLUSIONS: This Delphi study provides insights into the evolving role of adjuvant immunotherapy in localized RCC and relapse management. A multidisciplinary approach and periodic review are essential to optimizing treatment strategies.
引用
- Grünwald V, Bex A, Rottey S, et al. Current status of adjuvant immunotherapy and relapse management in renal cell carcinoma: Insights from a European delphi study. Eur J Cancer. 2025. PMID: 40516320. doi:10.1016/j.ejca.2025.115569
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。